About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Pittsburgh | 374 Studies

Clinical Trials Lung CancerPittsburgh

Lung Cancer Clinical Trials in Pittsburgh

Find 374 clinical trials for lung cancer near Pittsburgh, Pennsylvania. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Pittsburgh

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 61-80 of 374 trials

CompletedA Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung CancerThe purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.NCT00162318·Pittsburgh, Pennsylvania Active not recruitingA Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerThe purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor…NCT04487080·Goodyear, Arizona and 268 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingVeliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryThis phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see…NCT01386385·Anchorage, Alaska and 231 others

RecruitingFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCThe purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best…NCT06303505·Birmingham, Alabama and 28 others

TerminatedCisplatin and Nab-paclitaxel for (N2) Defined NSCLCThe purpose of this research study is to determine whether giving cisplatin and nab-paclitaxel before surgery will reduce the presence of disease in certain areas of the lung at…NCT02276560·Tampa, Florida and 8 others

CompletedA Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in…NCT01456325·Chandler, Arizona and 212 others

CompletedA Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus…NCT04623775·Duarte, California and 124 others

Active not recruitingTesting the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerThis phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small…NCT04310007·Birmingham, Alabama and 610 others

TerminatedA Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayThis is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849…NCT05578092·New Haven, Connecticut and 17 others

TerminatedStudy to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsRociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR)…NCT01526928·Duarte, California and 48 others

CompletedSafety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung CancerMaintenance treatment of advanced stage squamous cell NSCLC.NCT02027428·Huntsville, Alabama and 118 others

CompletedGSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsThe purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects…NCT03693612·Boston, Massachusetts and 7 others

TerminatedLIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung CancerThe purpose of the study is to evaluate the usefulness and accuracy of the "LIFE-Lung Bronchoscopy" to identify early changes in lung tissues that show precancerous, cancer in…NCT00260598·Pittsburgh, Pennsylvania

Active not recruitingStudy of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based…NCT02542293·Anaheim, California and 209 others

Active not recruitingStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationThis is a phase Ib/II open label study.NCT04699188·Atlanta, Georgia and 37 others

TerminatedM7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to…NCT03840902·Orange, California and 103 others

Active not recruitingStudy of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerThis study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the…NCT03539536·Mobile, Alabama and 251 others

TerminatedA Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsThe purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with advanced/metastatic lung cancer and fibroblast growth factor…NCT02109016·Los Angeles, California and 18 others

RecruitingA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCThe purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as…NCT06627647·Mobile, Alabama and 299 others

RecruitingA Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant…NCT05877599·Gilbert, Arizona and 22 others

PreviousPage 4 of 19Next

Other Conditions in Pittsburgh

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma